Terminal · Institutions
Every 13F-reported equity position this quarter, with its quarter-over-quarter change — each row traces back to the SEC filing.
Every 13F-reported equity position this quarter, with its quarter-over-quarter change — each row traces back to the SEC filing.
Siren, L.L.C. (CIK 2005245) reported $4.94B across 115 reported positions in its SEC 13F filing for 2026-06-30. Largest positions: SRRK ($526.6M, 10.66%), KYMR ($336.7M, 6.81%), ERAS ($208.8M, 4.23%), MANE ($203.5M, 4.12%), TNGX ($193.2M, 3.91%). Source: SEC Form 13F.
| Rank | Ticker | Company | Value | % Portfolio | Shares | Action |
|---|---|---|---|---|---|---|
| 1 | SRRK | Scholar Rock Holding Corp | $526.6M | 10.66% | 9.6M | Trimmed |
| 2 | KYMR | Kymera Therapeutics Inc | $336.7M | 6.81% | 2.9M | Trimmed |
| 3 | ERAS | Erasca Inc | $208.8M | 4.23% | 11.4M | Added |
| 4 | MANE | Veradermics Inc | $203.5M | 4.12% | 1.7M | Added |
| 5 | TNGX | Tango Therapeutics Inc | $193.2M | 3.91% | 6.2M | Added |
| 6 | RVMD | Revolution Medicines Inc | $168.6M | 3.41% | 900,000 | Trimmed |
| 7 | BCAX | Bicara Therapeutics Inc | $166.4M | 3.37% | 5.6M | Trimmed |
| 8 | ARWR | Arrowhead Pharmaceuticals Inc | $139.8M | 2.83% | 1.7M | Added |
| 9 | ONC | BeOne Medicines AG | $132.5M | 2.68% | 465,000 | Hold |
| 10 | EWTX | Edgewise Therapeutics Inc | $129.4M | 2.62% | 3.2M | Trimmed |
| 11 | RYTM | Rhythm Pharmaceuticals Inc | $126.2M | 2.55% | 1.1M | Added |
| 12 | LXRX | Lexicon Pharmaceuticals Inc | $106.3M | 2.15% | 44.3M | Hold |
| 13 | ELVN | Enliven Therapeutics Inc | $90.1M | 1.82% | 1.8M | Added |
| 14 | SYRE | Spyre Therapeutics Inc | $86.0M | 1.74% | 968,598 | Added |
| 15 | PBLS | Parabilis Medicines Inc | $81.9M | 1.66% | 3.0M | New |
| 16 | XENE | Xenon Pharmaceuticals Inc | $79.6M | 1.61% | 1.3M | Hold |
| 17 | ABVX | Abivax SA | $76.8M | 1.55% | 576,000 | New |
| 18 | COAG | Hemab Therapeutics Holdings Inc | $76.6M | 1.55% | 2.1M | New |
| 19 | SLDB | Solid Biosciences Inc | $76.8M | 1.55% | 7.7M | Hold |
| 20 | RCUS | Arcus Biosciences Inc | $74.6M | 1.51% | 2.4M | Trimmed |
| 21 | COGT | Cogent Biosciences Inc | $72.0M | 1.46% | 1.9M | Added |
| 22 | RLAY | Relay Therapeutics Inc | $68.3M | 1.38% | 3.6M | New |
| 23 | TSHA | Taysha Gene Therapies Inc | $67.1M | 1.36% | 9.8M | Added |
| 24 | DFTX | Definium Therapeutics Inc | $66.8M | 1.35% | 1.4M | Added |
| 25 | STOK | Stoke Therapeutics Inc | $65.3M | 1.32% | 2.0M | Hold |
Source: SEC Form 13F filings · as of 2026-06-30